JPWO2021007371A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021007371A5 JPWO2021007371A5 JP2022501134A JP2022501134A JPWO2021007371A5 JP WO2021007371 A5 JPWO2021007371 A5 JP WO2021007371A5 JP 2022501134 A JP2022501134 A JP 2022501134A JP 2022501134 A JP2022501134 A JP 2022501134A JP WO2021007371 A5 JPWO2021007371 A5 JP WO2021007371A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000012634 fragment Substances 0.000 claims 21
- 239000000427 antigen Substances 0.000 claims 20
- 108091007433 antigens Proteins 0.000 claims 20
- 102000036639 antigens Human genes 0.000 claims 20
- 108060003951 Immunoglobulin Proteins 0.000 claims 8
- 102000018358 immunoglobulin Human genes 0.000 claims 8
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 claims 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 102100036466 Delta-like protein 3 Human genes 0.000 claims 3
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 2
- 108090000695 Cytokines Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 102000004190 Enzymes Human genes 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229940127276 delta-like ligand 3 Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 239000002532 enzyme inhibitor Substances 0.000 claims 2
- 239000003102 growth factor Substances 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000003667 hormone antagonist Substances 0.000 claims 2
- 239000002502 liposome Substances 0.000 claims 2
- 239000002184 metal Substances 0.000 claims 2
- 229910052751 metal Inorganic materials 0.000 claims 2
- 239000002105 nanoparticle Substances 0.000 claims 2
- 201000002120 neuroendocrine carcinoma Diseases 0.000 claims 2
- -1 radionuclides Substances 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 239000003053 toxin Substances 0.000 claims 2
- 231100000765 toxin Toxicity 0.000 claims 2
- 108700012359 toxins Proteins 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 1
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 1
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 239000002872 contrast media Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088598 enzyme Drugs 0.000 claims 1
- 229940125532 enzyme inhibitor Drugs 0.000 claims 1
- 201000003445 large cell neuroendocrine carcinoma Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 150000002739 metals Chemical class 0.000 claims 1
- 230000002685 pulmonary effect Effects 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 208000000587 small cell lung carcinoma Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025061352A JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962872915P | 2019-07-11 | 2019-07-11 | |
| US62/872,915 | 2019-07-11 | ||
| PCT/US2020/041282 WO2021007371A1 (en) | 2019-07-11 | 2020-07-08 | Dll3-targeting antibodies and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Division JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022540611A JP2022540611A (ja) | 2022-09-16 |
| JP2022540611A5 JP2022540611A5 (https=) | 2023-07-12 |
| JPWO2021007371A5 true JPWO2021007371A5 (https=) | 2023-07-12 |
| JP7661299B2 JP7661299B2 (ja) | 2025-04-14 |
Family
ID=74115317
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022501134A Active JP7661299B2 (ja) | 2019-07-11 | 2020-07-08 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025061352A Pending JP2025156278A (ja) | 2019-07-11 | 2025-04-02 | Ｄｌｌ３をターゲッティングする抗体とその使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US12441789B2 (https=) |
| EP (1) | EP3997127A4 (https=) |
| JP (2) | JP7661299B2 (https=) |
| KR (1) | KR20220034167A (https=) |
| CN (3) | CN118955717A (https=) |
| AU (1) | AU2020310894A1 (https=) |
| BR (1) | BR112022000216A2 (https=) |
| CA (1) | CA3146566A1 (https=) |
| CO (1) | CO2022001195A2 (https=) |
| IL (1) | IL289585A (https=) |
| MX (1) | MX2022000325A (https=) |
| PH (1) | PH12022550056A1 (https=) |
| WO (1) | WO2021007371A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2718257T3 (https=) * | 2014-05-30 | 2018-04-14 | ||
| CN118955717A (zh) * | 2019-07-11 | 2024-11-15 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
| CA3204628A1 (en) * | 2021-01-13 | 2022-07-21 | John T. POIRIER | Antibody-pyrrolobenzodiazepine derivative conjugate |
| TW202245844A (zh) * | 2021-01-13 | 2022-12-01 | 紀念斯隆凱特琳癌症中心 | 抗dll3抗體-藥物結合物 |
| CN117529337A (zh) * | 2021-05-08 | 2024-02-06 | 上海齐鲁制药研究中心有限公司 | 针对dll3的结合分子及其应用 |
| JP2024532486A (ja) * | 2021-09-02 | 2024-09-05 | メモリアル スローン ケタリング キャンサー センター | Ｄｌｌ３を標的とする抗原認識受容体及びその使用 |
| WO2023034566A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Anti-dll3 antibodies and uses thereof |
| WO2023034557A1 (en) * | 2021-09-02 | 2023-03-09 | Memorial Sloan-Kettering Cancer Center | Radioligand binding to anti-dll3 antibodies for pretargeted pet imaging and therapeutic uses thereof |
| TW202346346A (zh) * | 2021-12-23 | 2023-12-01 | 大陸商江蘇恆瑞醫藥股份有限公司 | 抗ｄｌｌ３抗體、其抗體－藥物偶聯物及其醫藥用途 |
| KR20240149438A (ko) | 2022-02-27 | 2024-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | Cd277 및 종양-항원에 대한 이중특이적 항체 |
| CN116003628A (zh) * | 2022-08-15 | 2023-04-25 | 南京博安生物技术有限公司 | 靶向人dll3抗原的全人源特异性嵌合抗原受体及其应用 |
| WO2025184421A1 (en) * | 2024-02-28 | 2025-09-04 | Juno Therapeutics, Inc. | Chimeric antigen receptors and antibodies specific for delta-like ligand 3 (dll3) and related methods |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005016111A2 (en) | 2003-08-08 | 2005-02-24 | Abgenix, Inc. | Antibodies directed to parathyroid hormone (pth) and uses thereof |
| US7718774B2 (en) * | 2006-11-08 | 2010-05-18 | Macrogenics, Inc. | TES7 and antibodies that bind thereto |
| EP3907242A1 (en) * | 2010-01-29 | 2021-11-10 | Chugai Seiyaku Kabushiki Kaisha | Anti-dll3 antibody |
| WO2012013813A1 (en) | 2010-07-30 | 2012-02-02 | Gianluca Moroncini | Epitopes of the human pdgf receptor able to bind human auto-antibodies, antibodies and uses thereof |
| EP3453723B1 (en) * | 2012-01-31 | 2021-08-11 | Regeneron Pharmaceuticals, Inc. | Anti-asic1 antibodies and uses thereof |
| PE20190658A1 (es) * | 2012-02-24 | 2019-05-08 | Abbvie Stemcentrx Llc | Moduladores y metodos de empleo novedosos |
| PE20161209A1 (es) | 2014-02-21 | 2016-11-10 | Abbvie Stemcentrx Llc | Conjugados de anticuerpos anti-drosophila similar a delta 3 (anti-dll3) y medicamentos para usarse en el tratamiento contra melanoma |
| AR101669A1 (es) | 2014-07-31 | 2017-01-04 | Amgen Res Munich Gmbh | Constructos de anticuerpos para cdh19 y cd3 |
| RS61010B1 (sr) * | 2014-11-20 | 2020-11-30 | Hoffmann La Roche | Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije protiv folr1 i cd3 |
| CN118955717A (zh) * | 2019-07-11 | 2024-11-15 | 纪念斯隆凯特琳癌症中心 | Dll3靶向抗体及其用途 |
-
2020
- 2020-07-08 CN CN202411174926.2A patent/CN118955717A/zh active Pending
- 2020-07-08 PH PH1/2022/550056A patent/PH12022550056A1/en unknown
- 2020-07-08 CN CN202411174923.9A patent/CN119080930A/zh active Pending
- 2020-07-08 BR BR112022000216A patent/BR112022000216A2/pt unknown
- 2020-07-08 JP JP2022501134A patent/JP7661299B2/ja active Active
- 2020-07-08 EP EP20836805.0A patent/EP3997127A4/en active Pending
- 2020-07-08 CN CN202080062231.9A patent/CN114341182B/zh active Active
- 2020-07-08 AU AU2020310894A patent/AU2020310894A1/en active Pending
- 2020-07-08 WO PCT/US2020/041282 patent/WO2021007371A1/en not_active Ceased
- 2020-07-08 MX MX2022000325A patent/MX2022000325A/es unknown
- 2020-07-08 US US17/622,404 patent/US12441789B2/en active Active
- 2020-07-08 CA CA3146566A patent/CA3146566A1/en active Pending
- 2020-07-08 KR KR1020227004114A patent/KR20220034167A/ko active Pending
-
2022
- 2022-01-03 IL IL289585A patent/IL289585A/en unknown
- 2022-02-04 CO CONC2022/0001195A patent/CO2022001195A2/es unknown
-
2025
- 2025-04-02 JP JP2025061352A patent/JP2025156278A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023090710A5 (https=) | ||
| Welt et al. | Phase I study of anticolon cancer humanized antibody A33 | |
| CN105579471B (zh) | 结合人程序性死亡配体1(pd-l1)的抗体 | |
| JP5863201B2 (ja) | 単一特異性および多特異性抗体ならびに使用方法 | |
| JPWO2021007371A5 (https=) | ||
| JP7624497B2 (ja) | ヒトｐｄ－ｌ２抗体およびその使用方法 | |
| JP2008538289A5 (https=) | ||
| HRP20120701T1 (hr) | Humana monoklonska protutijela protiv fukozil-gm1 i postupci za uporabu antifukozil-gm1 | |
| JP2009100745A5 (https=) | ||
| JP2008538919A5 (https=) | ||
| US12325747B2 (en) | Human PD-L1 antibodies and methods of use therefor | |
| JP7713995B2 (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体およびその使用方法 | |
| JP2021515798A5 (https=) | ||
| RU2009137784A (ru) | Человеческое опухолеспецифическое моноклональное антитело | |
| EP3768726B1 (en) | Dual specificity antibodies to pd-l1 and pd-l2 and methods of use therefor | |
| JPWO2021046331A5 (https=) | ||
| KR20160144416A (ko) | 파클리탁셀의 약물동태-유도된 투여를 위해 혈장 중의 파클리탁셀 농도를 모니터링하는 방법, 장치 및 시약 | |
| JPWO2020210232A5 (https=) | ||
| RU2021139258A (ru) | Dll3-нацеливающие антитела и их применения | |
| JPWO2020264211A5 (https=) | ||
| JPWO2022032004A5 (https=) | ||
| JPWO2023186077A5 (https=) | ||
| JP2025512888A (ja) | ヒトｐｄ－ｌ１およびｐｄ－ｌ２に対する二重特異性抗体ならびにその使用方法 | |
| Handbook | MAKING AND USING ANTIBODIES | |
| Kit et al. | mAb anti-Human PSA, CHYH2, Dectector |